This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease
by Zacks Equity Research
Alnylam (ALNY) gets European approval for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1 in all age groups.
Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
Is a Surprise Coming for Alnylam (ALNY) This Earnings Season?
by Zacks Equity Research
Alnylam (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?
by Zacks Equity Research
Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
by Zacks Equity Research
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.
Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.
What's in the Cards for Cassava (SAVA) This Earnings Season?
by Zacks Equity Research
Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran
by Zacks Equity Research
Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.
Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data
by Zacks Equity Research
Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.